Introduction: BMS-663068 is a prodrug of BMS-626529, an attachment inhibitor that binds directly to HIV-1 gp120, preventing initial viral attachment and entry into the host CD4' T-cell. AI438011 is a Phase IIb, randomized, active-controlled trial investigating the safety, efficacy and doseÁresponse of BMS-663068 versus atazanavir/ritonavir (ATV/r) in treatmentexperienced (TE), HIV-1-positive subjects. Materials and Methods: Antiretroviral TE subjects (exposure to ]1 antiretroviral for ]1 week) with susceptibility to all study drugs (BMS-626529 IC 50 100 nM), were randomized equally to four BMS-663068 arms (400 or 800 mg, BID; 600 or 1200 mg, QD) and a control group (ATV/r 300/100 mg QD) with tenofovir disoproxil fumarate (TDF) ' raltegravir (RAL). A sub-group analysis of viral efficacy and immunologic reconstitution is presented. Results: A total of 251 subjects were treated. Median age was 39 years, 60% were male and 38% were white. Median baseline (BL) viral load (VL) was 4.85 log 10 c/mL (43%; 100,000 c/mL) and median CD4' T-cell count was 230 cells/mm 3 (38%; 200 CD4 cells/mm 3 ). Through Week 24, response rates (HIV-1 RNA 50 c/mL) were comparable across all BMS-663068 arms and the ATV/r arm regardless of gender, age and race. Response rates for subjects with BL VL 100,000 c/mL (BMS-663068, 82-96%; ATV/r, 93%) were higher than those for subjects with BL VL ]100,000 c/mL (BMS-663068, 70-87%; ATV/r, 73%); however, there were no substantial differences in response across the BMS-663068 and ATV/r arms in either sub-group. Response rates for subjects with BL CD4' cell counts ]200 cells/mm 3 (87-96%) were higher than those for subjects with BL CD4' cell counts 200 cells/mm 3 (62Á82%); however, no substantial differences in response were seen across the BMS-663068 and ATV/r arms in either subgroup. Mean changes in CD4' T-cell counts from BL were similar across all arms regardless of gender, age and BL CD4' T-cell count.
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